Fluconazol DeltaSelect

Fluconazol DeltaSelect may be available in the countries listed below.

Ingredient matches for Fluconazol DeltaSelect

Fluconazole

Fluconazole is reported as an ingredient of Fluconazol DeltaSelect in the following countries:

• Germany

International Drug Name Search

Gedun

Gedun may be available in the countries listed below.

Ingredient matches for Gedun

Gemfibrozil

Gemfibrozil is reported as an ingredient of Gedun in the following countries:

• Argentina

International Drug Name Search

Enalapril Marfan

Enalapril Marfan may be available in the countries listed below.

Ingredient matches for Enalapril Marfan

Enalapril

Enalapril is reported as an ingredient of Enalapril Marfan in the following countries:

• Peru

International Drug Name Search

Magnesium Peroxide

In some countries, this medicine may only be approved for veterinary use.

Scheme

Ph. Eur.

ATC (Anatomical Therapeutic Chemical Classification)

A02AA03,A06AD03

CAS registry number (Chemical Abstracts Service)

0014452-57-4

Chemical Formula

Mg-O2

Molecular Weight

56

Therapeutic Categories

Antacid

Laxative, osmotically acting

Foreign Names

• Magnesii peroxidum (Latin)
• Magnesium peroxid (German)
• Peroxyde de magnésium (French)
• Peróxido de magnesio (Spanish)

Generic Names

• Magnesium dioxide (IS)
• Magnesium perhydrolum (IS)
• Magnesium superoxol (IS)
• Peromag (IS)
• Magnesium Peroxide (PH: Ph. Eur. 6)

Brand Names

• Ektozon N (Magnesium Peroxide and Sodium Perborate (veterinary use))
  Delphin-Amazonia, Switzerland



• Ozovit
  Pascoe, Germany

International Drug Name Search

Glossary

IS	Inofficial Synonym
PH	Pharmacopoeia Name
Ph. Eur.	European Pharmacopoeia

Click for further information on drug naming conventions and International Nonproprietary Names.

Fusibact B

Fusibact B may be available in the countries listed below.

Ingredient matches for Fusibact B

Betamethasone

Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Fusibact B in the following countries:

• Oman

Fusidic Acid

Fusidic Acid is reported as an ingredient of Fusibact B in the following countries:

• Oman

International Drug Name Search

Secnidazol MK

Secnidazol MK may be available in the countries listed below.

Ingredient matches for Secnidazol MK

Secnidazole

Secnidazole is reported as an ingredient of Secnidazol MK in the following countries:

• Colombia


• Ecuador

International Drug Name Search

Zytiga

Zytiga is a brand name of abiraterone, approved by the FDA in the following formulation(s):

ZYTIGA (abiraterone acetate - tablet; oral)

• 
  Manufacturer: JANSSEN BIOTECH
  
  Approval date: April 28, 2011
  
  Strength(s): 250MG ^[RLD]

Has a generic version of Zytiga been approved?

No. There is currently no therapeutically equivalent version of Zytiga available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zytiga. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  17-substituted steroids useful in cancer treatment
  Patent 5,604,213
  Issued: February 18, 1997
  Inventor(s): Barrie; Susan E. & Jarman; Michael & Potter; Gerard A. & Hardcastle; Ian R.
  Assignee(s): British Technology Group Limited
  Compounds of the general formula (1) ##STR1## wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R.sup.14 represents a hydrogen atom and R.sup.15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R.sup.14 and R.sup.15 together represent a double bond, and R.sup.16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or phannaceutically acceptable acid addition salts, are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.
  
  Patent expiration dates:
  
  
  • February 18, 2014
    
    ✓ 
    Patent use: USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 28, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Zytiga Consumer Information (Drugs.com)
• Zytiga Suspension Consumer Information (Wolters Kluwer)
• Zytiga Consumer Information (Cerner Multum)
• Zytiga Advanced Consumer Information (Micromedex)
• Abiraterone Consumer Information (Cerner Multum)
• Abiraterone Advanced Consumer Information (Micromedex)